Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients

Journal of Clinical Investigation

Volumn 99, Issue 6, 1997, Pages 1272-1280

  Niwa, Toshimitsu ^a   Katsuzaki, Tomoyuki ^b   Miyazaki, Shigeru ^c   Miyazaki, Takashi ^a   Ishizaki, Yayoi ^a   Hayase, Fumitaka ^d   Tatemichi, Noriyuki ^b   Takei, Yoshifumi ^b  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b Maruko Pharmaceutical Co Ltd   (Japan)

^c Shinrakuen Hospital   (Japan)

^d MEIJI UNIVERSITY   (Japan)

Author keywords

atherosclerosis; diabetes mellitus; imidazolone; Maillard reaction; nephropathy

Indexed keywords

GLYCOSYLATED PROTEIN; IMIDAZOLONE; UNCLASSIFIED DRUG;

ADULT; AGED; AORTA; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY; MALE; PRIORITY JOURNAL;

EID: 0030901310     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119285     Document Type: Article

References (47)

1. Kato, H., D.B. Shin, and F Hayase. 1987. 3-Deoxyglucosone crosslinks proteins under physiological conditions. Agric. Biol. Churn. 51:2009-2011.
2. Shin, D.B., F. Hayase, and H. Kato. 1988. Polymerization of proteins caused by reaction with sugars and the formation of 3-deoxyglucosone under physiological conditions. Agric. Biol. Chem. 52:1451-1458.
3. Kato, H. 1962. Chemical studies on amino-carbonyl reaction. Part I. Isolation of 3-deoxypentosone and 3-deoxyhexosones formed by browning degradation of N-glycosides. Agric. Biol. Chem. 26:187-192.
4. Kato, H., R.K. Cho, A. Oitani, and F. Hayase. 1987. Responsibility of 3-deoxyglucosone for the glucose-induced polymerization of proteins. Agric. Biol. Chem. 51:683-689.
5. ∈-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry. 34:10872-10878.
6. Njoroge, F.G., L.M. Sayre, and V.M. Monnier. 1987. Detection of glucose-derived pyrrole compounds during Maillard reaction under physiological conditions. Carbohydr. Res. 167:211-220.
7. Sell, D.R., and V.M. Monnier. 1989. Structure elucidation of a senescence cross-link from human extracellular matrix. J. Biol. Chem. 264:21597-21602.
8. Nakamura, K., T. Hasegawa, Y. Fukunaga, and K. Ienaga. 1992. Crosslines A and B as candidates for the fluorophores in age- and diabetes-related cross-linked proteins, and their diacetates produced by Maillard reaction of α-N-acetyl-L-lysine with D-glucose J. Chem. Soc. Chem. Commun. 14: 992-994.
9. Brownlee, M., N. Vlassara, and A. Cerami. 1984. Nonenzymatic glycation and the pathogenesis of diabetic complications. Ann. Intern. Med. 101:527-537.
10. Kennedy, L., and J.W. Baynes. 1984. Nonenzymatic glycosylation and chronic complications of diabetes: an overview. Diabetologia. 27:92-98.
11. Monnier, V.M., R.R. Kohn, and A. Cerami. 1984. Accelerated age-related browning of human collagen in diabetes mellitus. Proc. Natl. Acad. Sci. USA. 81:583-587.
12. Makita, Z., H. Vlassara, E. Rayfield, K. Cartwright, E. Friedman, R. Rodby, A. Cerami, and R. Bucala. 1992. Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science (Wash. DC). 58:651-653.
13. Araki, N., N. Ueno, B. Chakrabarti, Y. Morino, and S. Horiuchi. 1992. Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J. Biol. Chem. 267:931-939.
14. 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J. Clin. Invest. 92:1243-1252.
15. 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. J. Clin. Invest. 93:521-528.
16. Niwa, T., T. Miyazaki, T. Katsuzaki, N. Talemichi, Y. Takei, T. Miyazaki, T. Morita, and Y. Hirasawa. 1995. Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis. Kidney Int. 48: 771-778.
17. 2-microglobulin with advanced glycation end products as observed in dialysis-related amyloidosis by 3-deoxyglucosone accumulating in uremic serum. Kidney Int. 49:861-867.
18. ∈-(carboxymethyl)lysine in dialysis-related amyloidosis. Kidney Int. 50:1303-1309.
19. Vitek, M.P., K. Bhattacharya, J.M. Glendening, E. Stopa, H. Vlassara, R. Bucala, K. Manogue, and A. Cerami. 1994. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 91:4766-4770.
20. Smith, M.A., S. Taneda, P.L. Richey, S. Miyata, S.D. Yan, D. Stern, L.M. Saver, V.M. Monnier, and G. Perry. 1994. Advanced Maillard reaction end products are associated with Alzheimer disease. Proc. Natl. Acad. Sci. USA. 91:5710-5714.
21. Yan, S.D., X. Chen, A.M. Schmidt, J. Brett, G. Godman, Y.S. Zou, C.W. Scott, C. Caputo, T. Frappier, M.A. Smith, G. Perry, S.H. Yen, and D. Stern. 1994. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc. Natl. Acad. Sci. USA. 91:7787-7791.
22. Makita, Z., S. Radoff, E.J. Rayfield, Z. Yang, E. Skolnik, V. Delaney, E.A. Friedman, A. Cerami, and H. Vlassara. 1991. Advanced glycation end products in patients with nephropathy. N. Engl. J. Med. 325:836-842.
23. Makita, Z., R. Bucala, E.J. Rayfield, E.A. Friedman, A.M. Kaufman, S.M. Korbet, R.H. Barth, J.A. Winston, H. Fuh, K.R. Manogue, A. Cerami, and H. Vlassara. 1994. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet. 343:1519-1522.
24. Miyata, S., and V. Monnier. 1992. Immunohistochemical detection of advanced glycation end products in diabetic tissues using monoclonal antibody to pyrraline. J. Clin. Invest. 89:1102-1112.
25. Makino, H., K. Shikata, K. Hironaka, M. Kushiro, Y. Yamasaki, H. Sugimoto, Z. Ota, N. Araki, and S. Horiuchi. 1995. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int. 48:517-526.
26. Hayase, F., R.H. Nagaraj, S. Miyata, F.G. Njoroge, and V.M. Monnier. 1989. Aging of proteins: immunological detection of a glucose-derived pyrrole formed during Maillard reaction in vivo. J. Biol. Chem. 263:3758-3764.
27. Dyer, D.G., J.A. Blackledge, S.R. Thorpe, and J.W. Baynes. 1991. Formation of pentosidine during nonenzymatic browning of proteins by glucose. J. Biol. Chem. 266:11654-11660.
28. Szwergold, B.S., F. Kappler, and T.R. Brown. 1990. Identification of fructose 3-phosphate in the lens of diabetic rats. Science (Wash. DC). 247:451-454.
29. Niwa, T., N. Takeda, H. Yoshizumi, A. Tatematsu, M. Ohara, S. Tomiyama, and K. Niimura. 1993. Presence of 3-deoxyglucosone, a potent protein crosslinking intermediate of Maillard reaction, in diabetic serum. Biochem. Biophys. Res. Commun. 196:837-843.
30. Niwa, T., N. Takeda, T. Miyazaki, H. Yoshizumi, A. Tatematsu, K. Maeda, M. Ohara, S. Tomiyama, and K. Niimura. 1995. Elevated serum levels of 3-deoxyglucosone, a potent protein-cross-linking intermediate of the Maillard reaction, in uremic scrum. Nephron. 69:438-443.
31. Konishi, Y., F. Hayase, and H. Kato. 1994. Novel imidazolones compound formed by the advanced Maillard reaction of 3-deoxyglucosone and arginine residues in proteins. Biosci. Biotechnol. Biochem. 58:1953-1955.
32. Hayase, F., Y. Konishi, and H. Kato. 1995. Identification of the modified structure of arginine residues in proteins with 3-deoxyglucosone, a Maillard reaction intermediate. Biosci. Biotechnol. Biochem. 59:1407-1411.
33. Kato, Y., K. Tokunaga, and T. Osawa. 1996. Immunochemical detection of carboxymethylated Apo B-100 in copper-oxidized LDL. Biochem. Biophys. Res. Commun. 226:923-927.
34. Lo, T.W.C., M.E. Westwood, A.C. McLellan, T. Selwood, and P.J. Thornalley. 1994. Binding and modification of proteins by methylglyoxal under physiological conditions. J. Biol. Chem. 269:32299-32305.
35. Soulis-Liparota, T., M. Cooper, D. Papazoglou, B. Clarke, and G. Jerums. 1991. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rats. Diabetes. 40:1328-1334.
36. Edelstein, D., and M. Brownlee. 1992. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes. 41:26-28.
37. Vlassara, H., L.J. Striker, S. Teichberg, H. Fuh, Y.M. Li, and M. Steffes. 1994. Advanced glycalion end products induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. USA. 91:11704-11708.
38. Nakamura, Y., Y. Horii, T. Nishino, H. Shiiki, Y. Sakaguchi, T. Kagoshima, K. Dohi, Z. Makita, H. Vlassara, and R. Bucala. 1993. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol. 143:1649-1656.
39. Kume, S., M. Takeya, T. Mori, N. Araki, H. Suzuki, S. Horiuchi, T. Kodama, Y. Miyauchi, and K. Takahashi. 1995. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am. J. Pathol. 147:654-667.
40. Vlassara, H., H. Fuh, T. Donnelly, and M. Cybulsky. 1995. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol. Med. 1:447-456.
41. Schmidt, A.M., O. Hori, J.X. Chen, J.F. Li, J. Crandall, J. Zhang, R. Cao, S.D. Yan, J. Brett, and D. Stern. 1995. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 96:1395-1403.
42. Brownlee, M., H. Vlassara, and A. Cerami. 1985. Nonenzymatic glycosylation products on collagen covalently trap low density lipoprotein. Diabetes. 34:938-941.
43. Bucala, R., K.J. Tracey, and A. Cerami. 1991. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest. 87:432-438.
44. Hogan, M., A. Cerami, and R. Bucala. 1992. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J. Clin. Invest. 90:1110-1115.
45. Kirstein, M., J. Brett, S. Radoff, S. Ogawa, D. Stern, and H. Vlassara. 1990. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc. Natl. Acad. Sci. USA. 87:9010-9014.
46. Bucala, R., Z. Makita, G. Vega, S. Grundy, T. Koschinsky, A. Cerami, and H. Vlassara. 1994. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc. Natl. Acad. Sci. USA. 91:9441-9445.
47. Steinberg, D., S. Parthasarathy, T.E. Carew, J.C. Khoo, and J.L. Witztum. 1989. Beyond cholesterol. Modifications of low density lipoprotein that increases its atherogenicity. N. Engl. J. Med. 320:915-924.